Keywords: XOMA, Servier, Boehringer Ingelheim, Gevokizumab, Manufacturing, Behcet's uveitis

XOMA and Servier sign manufacturing deal with Boehringer for gevokizumab

Article | 06 August 2012

Print This

US therapeutic antibody discovery firm XOMA Corp (Nasdaq: XOMA) its partner France’s Laboratoires Servier have entered into an ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in